Stock Ratings / Health Care / KARD / dividends

NKTR (33) DMRA (47) OMER (46) KRSA (33) ⌘ Pro Terminal →

Kardigan Inc. (KARD) Dividend Safety Gauge & 10-Year DRIP Compounder

$14.31 +4.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Kardigan Inc. (KARD) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.34B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KARD)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in KARD & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on KARD and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KARD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.95%▼ DESCENDING CHANNEL

2026-10-30O $14.25H $14.65L $13.75C $14.31VOL 452.8K

RES: $18.51SUP: $9.68SMA50: $16.33SMA200: $18.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KARD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KARD Butterfly Map → + Track KARD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KARD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KARD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KARD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KARD)

Health Care Rank #186 of 1016 ⚔️ NKTR vs KARD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KARD vs. NKTR, DMRA, OMER, KRSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kardigan Inc. (KARD) ranks #186 by composite RQD confidence (61/100, grade C-) and #321 by equity capitalization ($1.34B). Within this direct 5-issuer industry benchmark cohort, KARD leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KARD ACTIVE Kardigan Inc.	C-	61/100	—	—	—	+4.22%	$1.34B	Benchmark Subject
NKTR Nektar Therapeutics	E	33/100	—	96.0%	-35.0%	+1.63%	$1.34B	/nktr-vs-kard →
DMRA Damora Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.85%	$1.36B	/dmra-vs-kard →
OMER Omeros Corporation	D	46/100	—	—	-35.0%	+5.98%	$1.37B	/omer-vs-kard →
KRSA Korsana Biosciences Inc.	E	33/100	—	—	-5.7%	+0.37%	$1.38B	/krsa-vs-kard →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002123613

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kardigan Inc. (KARD) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KARD closed FY2025 with $390.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$390.9M	—

3. KARD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KARD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kardigan Inc. (NASDAQ: KARD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $14.31 (+4.22% 1D, market cap $1.34B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KARD ranks #186 in composite RQD confidence.

How does KARD compare to NKTR and DMRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KARD carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NKTR (Nektar Therapeutics) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.34B) and DMRA (Damora Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.36B). Among the 5-stock peer group, KARD leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KARD?

Per KARD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002123613), Kardigan Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $390.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KARD trading relative to its 50-day, 200-day, and 52-week technical levels?

KARD last traded at $14.31 (+4.22% on volume of 446,399 shares), positioning the stock -12.37% below its 50-day simple moving average ($16.33) and -24.60% below its 200-day simple moving average ($18.98). Across its 52-week range of $12.23 to $27.00, KARD sits at the 14.1% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.52 to $16.10).

KARD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does KARD pay a dividend and is it safe?

Kardigan Inc. (KARD) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: KARD RQD Cockpit KARD 12M Forecast KARD Earnings & Move KARD Dividends & DRIP KARD Insiders & 13F KARD Whale Options KARD Profit Sankey KARD News & Why